Assisted fertilization with own oocytes in women over 40 years of age: indications and results

Jaime Seminario Agurto1,a, Alicia Seminario Vargas1,b, Jimmy Portella Ruiz1,c

DOI: https://doi.org/10.31403/rpgo.v69i2551

ABSTRACT

Women postpone motherhood because of their desire for personal and professional improvement. It is known that the quantity and quality of oocytes per cycle depends on the patient's age. Success rates in assisted reproduction treatments decrease with age, especially after 40 years of age. Higher live birth rates are observed in younger women, and rates decrease significantly in older women due to decreased fertility and increased miscarriages. Therefore, age is crucial when assessing the possibility of a successful pregnancy through assisted reproductive treatments (ART). The indications to perform in vitro fertilization (IVF) with own ovules in women older than 40 years include starting as soon as possible highly complex procedures, good evaluation of ovarian reserve with antimüllerian hormone analysis (AMH) and antral follicle count (AFC) for genetic counseling, proposing IVF-intracytoplasmic sperm injection (ICSI) before the age of 44 years, generating realistic expectations and informed consent, with own statistics. At REDLARA, of all IVF-ICSI procedures, 34% of patients are over 40 years old; preference is given to transfer blastocysts with preimplantation genetic testing for aneuploidy (PGT-A) to select euploid embryos. Success rates are low, even when they are pregnancy rates per embryo transfer in the group of women ≥ 40 years (18.2% without PGT, 42.7% with PGT in IMRCRP). It is recommended to bank ovules or embryos by performing multiple ovarian stimulations. A single embryo transfer should be chosen to avoid obstetric complications with multiple pregnancies in patients ≤ 40 years, because of the high risk due to age.

Key words: Reproductive techniques, assisted, Age factors, Pregnancy rates, Ovarian reserve

RESUMEN

Las mujeres posponen su maternidad por el deseo de superación personal y profesional. Se conoce que la cantidad y calidad de los óvulos por ciclo dependen de la edad de la paciente. Las tasas de éxito en tratamientos de reproducción asistida disminuyen con la edad, especialmente después de los 40 años. Se observan tasas más altas de nacidos vivos en mujeres más jóvenes y las tasas disminuyen significativamente en mujeres mayores debido a la disminución de la fertilidad y el aumento de abortos espontáneos. Por ello, la edad es crucial al evaluar la posibilidad de un embarazo exitoso mediante tratamientos de reproducción asistida (TRA). Las indicaciones para realizar fertilización in vitro (FIV) con óvulos propios en mujeres mayores de 40 años incluyen iniciar lo más pronto procedimientos de alta complejidad, buena evaluación de la reserva ovárica con análisis de la hormona antimülleriana y conteo de folículos antrales para realizar asesoramiento genético, proponer FIV-inyección intracitoplasmática de espermatozoides (ICSI) antes de los 44 años, generar expectativas realistas y realizar consentimiento informado, con estadísticas propias. En la REDLARA, de todos los procedimientos de FIV-ICSI, el 34% de las pacientes tienen más de 40 años; se prefiere transferir blastocistos con prueba genética preimplantacional de aneuploidías (PGT-A) para seleccionar embriones euploides. Las tasas de éxito son bajas, inclusive cuando son tasas de embarazo por transferencia de un embrón en el grupo de mujeres ≥ 40 años (18.2% sin PGT, 42.7% con PGT en IMRCRP). Se recomienda acumular óvulos o embriones realizando múltiples estimulaciones ováricas. Se debe optar por transferir un solo embrión para evitar complicaciones obstétricas con embarazos múltiples en pacientes ≥ 40 años, por el alto riesgo debido a la edad.

Palabras clave: Técnicas reproductivas asistidas, Factores de edad, Tasa de embarazo, Reserva ovárica

Rev Peru Ginecol Obstet. 2023;69(3) 1
In the last decades, women have important roles in society, with jobs, projects and personal goals, so they postpone motherhood. In addition, national and private social insurance do not cover assisted reproduction treatments (ART). For this reason, the age group of our patients is older than those seen in other countries.

In the case of a patient over 40 years of age, it is important to evaluate the possibility of having a healthy baby. Fertility rates decline over the years, 4%-8% lower in women ages 25-29, 15%-19% lower in women aged 30-34, 26%-46% lower in women aged 35-39 years and up to 95% lower in women aged 40-45 years\(^{(1,2)}\).

Success rates achieved with ART using one’s own oocytes decrease with increasing age, because the number of oocytes retrieved, embryos available, implantation, pregnancy and live birth rates are lower in older women. Annual reports from the Centers for Disease Control and Prevention (CDC) in the United States since 1989 consistently show that age is the single most important factor affecting the likelihood of success with ART. Pregnancy and live birth rates for ART cycles using fresh own embryos or eggs vary little for women under age 32, but then consistently decline in a nearly linear fashion with increasing age. This occurs regardless of whether success rates are calculated per cycle, per oocyte aspiration or per embryo transfer.

In the 2021 U.S. Society for Assisted Reproductive Technology (SART) national summary, the live birth rate per embryo transfer was 52.5% for women younger than 35 years, 42% for those aged 35-37 years, 28.4% for those aged 38-40 years, 13.3% for those aged 41-42 years and 4.3% for women aged 43-44 years, despite the fact more embryos are transferred to older women\(^{(3)}\). Age is not only related to decreased fertility with ART, but also to an increased miscarriage rate (Figure 1). Miscarriage rates in natural conception cycles are generally low before the age of 30 (7%-15%) and increase with age only slightly between ages 30-34 (8%-21%) but is highest between 35-39 years (17%-28%) and over 40 years (34%-52\%)\(^{(4-6)}\). The same pattern is observed in pregnancies resulting from ART. In the U.S. national summary of ART outcomes in 2021, miscarriage rates were below 15% in women younger than 35 years, almost 29% at 40 years, and 65% in women aged 44 years and older\(^{(4-6)}\).

There is a good correlation between age at menopause in mothers and daughters and between sisters, suggesting that genetic factors play an important role in determining the age of menopause\(^{(21-23)}\). Approximately 10% of women reach menopause at age 45 years\(^{(13,24)}\), probably because they have a smaller ovarian follicular reserve that is depleted at an earlier age.

Likewise, women who repeatedly have a poor response to exogenous gonadotropin stimulation also tend to have an earlier menopause\(^{(25-28)}\). This suggests that their poor response reflects an advanced stage of follicular depletion that begins years earlier than normally expected\(^{(26)}\).

While the number of remaining ovarian follicles steadily decreases with increasing age, observations in stimulated cycles suggest that aged follicles also become progressively less sensitive to gonadotropin stimulation. As age increases, the
drug dose and duration of treatment need to be increased to stimulate multiple follicular development. The rise and peak of estradiol levels decreases which is reflected in smaller cohorts of follicles that can be recruited. However, the amount of estradiol secreted by follicles that emerge and grow to maturity appears comparable to that of younger women.[29]

In studies of ovarian follicular development and preovulatory follicular fluid hormone levels in both older and younger (ovulatory) women, no age-related decrease in follicular function is found once growth and development begin. Preovulatory follicles in older and younger women are similar in size and the follicular fluid contains the same levels of inhibin and progesterone; estrogen/androgen ratios are even higher in older women than in younger women.[29].

Older women ovulate as regularly and more frequently than younger women. Apparently their increasing FSH levels compensate quite effectively for any decrease in follicular sensitivity to gonadotropin stimulation. Preovulatory follicles in cycles of older women start earlier but grow at a normal rate and reach a normal size; the characteristics of the follicular fluid suggest that they are also quite healthy.

**Why then does fertility in women decline progressively with age?**

The available evidence indicates that both the age-related decline in female fertility and the increased risk of miscarriage can be attributed to an increase in the proportion of abnormal oocytes in an aging and shrinking follicular pool.

As the number of follicles decreases, oocyte quality also decreases, primarily due to an increased lack of meiotic disjunction, resulting in an increasing rate of oocyte and embryo aneuploidy in aging women.[31-34].

**Genetic alterations**

A wide variety of techniques have been used to study the chromosomal composition of human oocytes. The best available evidence derived from detailed cytogenetic analysis of oocytes retrieved for IVF that failed to fertilize suggests that the overall rate of oocyte aneuploidy increases with advancing maternal age.[35,36].

An analysis of trophectoderm biopsies from more than 15,000 human blastocysts also showed that the rate of aneuploidy increases with age. This is true for all chromosomes and is highest for chromosomes 15, 16, 18, 19, 21, and 22.[37]. Other embryonic factors beside aneuploidy could influence the competence of euploid embryos in an age-dependent manner.

Changes in embryonic gene expression, metabolism, and epigenetic health may explain the adverse fate of some euploid embryos. For example, advanced paternal age (which is often associated with advanced maternal age) is thought to contribute to alterations in early embryonic growth through nongenetic mechanisms. Aging-induced hypomethylation at specific binding sites in the sperm genome may be a key molecular feature that modulates embryonic and offspring.[38].

The age-related increase in aneuploidy was most pronounced for acrocentric chromosomes (where the centromere is located near one end of the chromosome, e.g., chromosome 21)[37] (Figure 2).

In summary, accumulating evidence strongly suggests that the primary cause of age-dependent fertility decline and increased incidence of miscarriage is an increasing prevalence of aneuploidy in aging oocytes as a result, at least in part, of disordered regulatory mechanisms governing meiotic spindle formation and function.

**Uterine disorders**

In the past it was mentioned that age did not seem to generate any significant adverse effects on the uterus. Recent findings suggest that age significantly affects endometrial gene expres-
sion and that major changes in endometrial function occur after 35 years (39). Using a non-genome-wide functional approach, changes in age-affected molecular processes in the endometrium have been observed, including reduced epithelial cell proliferation due to cell cycle arrest and upregulation of ciliary processes.

Likewise, the incidence of myomas is known to increase with age. And the perception of adenomyosis is that it affects older women of reproductive age. Adenomyosis and uterine fibroids, by modifying the vascular architecture, altering normal contractility and changing the production of angiogenic factors, could alter the local and distant endometrial milieu and, consequently, endometrial function. We cannot exclude that other lesser-known factors may be consistent with our findings (40-42).

However, there is still limited evidence to suggest that uterine age itself has an important impact on fertility (43-45). With increasing maternal age, there is an increased risk of a history of uterine surgery (especially cesarean sections and myomectomies) and disorders of glucose metabolism. Both of these factors have been strongly associated with an increased risk of miscarriage in a recent large prospective registry-based study (46,47). In addition, an increased risk of miscarriage is observed in patients with positive thyroid autoantibodies. The exact pathophysiological mechanism remains controversial, but it is known that euthyroid women with positive thyroid autoantibodies are older than euthyroid women with negative autoantibodies (48).

Ovarian reserve

The term ovarian reserve refers to: 1) the size and quality of follicles that her ovaries have, and 2) the ability of the ovaries to respond to exogenous gonadotropin stimulation, which are related concepts. Since the main effect of aging on a woman’s reproductive potential is a decrease in the number of oocytes and an increase in oocyte aneuploidy, the concept of ovarian reserve is relevant to female reproductive aging.

Ovarian reserve testing serve two purposes: 1) to predict fertility and 2) to obtain prognostic information about the likelihood of a successful response to ovarian stimulation in women undergoing infertility treatment.

Ovarian reserve testing in this age group is intended to identify women with ‘diminished ovarian reserve’ (DOR). It is important to emphasize that such tests cannot and do not establish a diagnosis of DOR; they only identify women who are more likely to show a poor response to gonadotropin stimulation and potentially have a lower likelihood of achieving pregnancy with treatment.

Anti-Müllerian hormone (AMH) dosing and antral follicle count at the beginning of the cycle are primarily used to determine ovarian reserve. The quality of the oocytes is predicted by the patient’s age.

Ovarian reserve testing has also become a routine element of the diagnostic evaluation of infertility. Proponents of the liberal application of ovarian reserve testing argue that abnormal tests can help persuade older women to abandon plans to pursue aggressive, expensive, and probably futile treatment, and convince younger women to do the exact opposite in order to make the most of a rapidly closing window of opportunity.

Ovarian reserve tests should always be interpreted with caution. Rigid application of test results runs the risk of inappropriate recommendations for treatment, or for no treatment, and both should be avoided. An abnormal test result does not exclude the possibility of pregnancy. Except perhaps when very abnormal, test results should not be used to deny treatment, but only to obtain prognostic information that can help guide the choice of treatment and the best use of available resources. Although the chance of pregnancy may be low, many individuals with abnormal test results will achieve pregnancy if given the opportunity. Ultimately, regardless of the prognosis, the success rate for any woman will be 0% or 100%.

**Indications for IVF with own oocytes in women over 40 years old**

Older age presents additional challenges and considerations compared to younger women. The main objective is to achieve a euploid embryo, i.e., a healthy baby.

1. Decrease the search time: achieving pregnancy unaided or with low complexity procedures generates very low success rates. Therefore, it should be proposed to start IVF as soon as possible.
2. Genetic counseling: in order to reduce the miscarriage rate, it is acceptable to perform a genetic study on the embryos in order to rule out aneuploidies (PGT-a).

3. Consider patients ideally under 44 years of age because the newborn rate (NB) is 2%.

4. Evaluation of the ovarian reserve and that it is within acceptable ranges, considering mainly the AMH and the antral follicle count.

5. Realistic expectations: desire to attempt IVF procedures despite knowing the low results. Recognize and accept the possibility of obtaining a reservoir of embryos.

6. Finally, sign a special informed consent oriented to the patients over 40 years of age pointing out the live birth rates (LBR) offered by the center itself.

**Ovarian stimulation in women over 40 years old**

The dose to be administered for stimulation depends on the ovarian reserve. If this is adequate, full doses should be administered.

On the contrary, if the ovarian reserve is diminished (2-3 antral follicles), it is suggested that the stimulation be minimal and consider performing multiple cycles, with the objective of having at least 3 embryos to send for preimplantation genetic test (PGT); this procedure is called embryo accumulation and/or banking.

We present a group of patients from the Institute of Reproductive Medicine of the Ricardo Palma Clinic who performed banking (49) (figure 3).

The accumulation of embryos proposed in this group of patients in order to increase the possibilities of having euploid embryos and the chance of a transfer was also analyzed by our group. In Figure 3 we present the number of consecutive cycles of hormonal stimulation performed in some patients. A first cycle of ART was performed in 510 patients; of these, 173 had a second cycle, 57 a third cycle, 23 a fourth cycle, and so on to 1 patient who completed 9 cycles. With each new cycle, an increase in the average number of fertilized oocytes is observed. However, the average number of blastocysts and euploid blastocysts does not increase at the same rate.

**Results**

The Latin American Network for Assisted Reproduction (REDLARA) began in 1990 as the first multinational and regional registry of assisted reproductive technologies (ART). As in previous years, the latest report No. 32 provides information on the utilization, availability, effectiveness, safety and perinatal outcomes of ART initiated between January 1 and December 31, 2020, and newborn rates through September 2021 (50). ART data were collected from 188 centers in 16 Latin American countries, covering IVF cycles with fresh own oocytes and intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), frozen embryo transfer (FET) preceded by both fresh embryo transfer and frozen own oocyte cycles, oocyte donation including fresh and frozen embryo transfer, fertility preservation, and both own and donated thawed oocyte cycles. The 87,732 cycles initiated during 2020 resulted in 12,778 deliveries and 14,405 live births.

As seen in Figure 4, in the last 7 years, the proportion of women aged 34 years or younger has decreased from 31.7% to 24.7% and women ≥ 40 have continued to increase from 27% to 34%. 75.3% of women treated in the region were aged 35 years or older, with profound variations between countries. The proportion of women ≥ 40 in the main contributors was: Brazil 35.3%, Mexico 25.3%, Argentina 41.9% and Peru 40.4%. This is very important when comparing the results of IVF/ICSI treatment outcomes between different countries and regions. The proportion of women ≥ 40 is only 18% in Europe and approximately 26% in the USA.

**Outcome of fresh and frozen IVF and ICSI cycles with own oocytes by woman’s age and number of embryos transferred**

In 2020, there were 39,418 fresh IVF/ICSI cycles initiated, but as reported in Figure 5, after discarding canceled cycles, frozen cycles, and other conditions preventing embryo transfer reduced the number of cycles in which at least one mature oocyte was collected to 17,253. In addition, after discarding cases with failed fertilization, no embryo development and PGT cases without normal embryos, the number of transfer cycles was further reduced to 11,101. Table 1 provides the clinical pregnancy rates (CPR) and delivery
rates per obtained oocyte and embryo transfer according to the age of the woman and the type of fertilization process.

In the REDLARA report, as in previous years, ICSI accounts for 84.8% of transfers. This high proportion of ICSI with no clear explanation beyond fear of fertilization failure has remained stable in the last decade, 85.7% in the 2010 report. When stratified by age of the female partner, the pregnancy rate per oocyte retrieved was significantly higher in IVF than in ICSI only in women ≥ 35 years old (p < 0.0001). However, there was no difference in the delivery rate per oocytes retrieved and the delivery rate per embryo transfer. As expected, the chances of achieving a delivery decreased with age.

The rates differed when transferring 1 embryo or 2 embryos; or when transferring 1 embryo only having others, i.e., choosing the best one, compared to when it is the only embryo, i.e., no more embryos are available. Generally, in women ≥ 40, only 1 embryo is available.

In REDLARA, the proportion of blastocyst stage embryos transferred over dividing embryos increases year after year. This proportion represented 30.3% of all transfers in 2016, increasing to 77.6% in 2020. And, as mentioned above, in CPR cases it accounted for 86.8% of all transfers compared to 53.3% in fresh IVF/ICSI. When comparing the delivery rate and multiple birth rate after elective 8-cell splitting embryo transfer (day 3) and elective day 5 blastocyst transfer in IVF and ICSI cycles, the delivery rates were significantly higher after blastocyst transfer.

**Influence of PGT on the TRA outcome**

Over the past 5 years, the proportion of aspirations leading to PGT has increased nearly 2.5-fold across all age categories (Figure 6). In 2020, a total of 144/188 centers (76.6%) reported 8,920 aspirations from fresh cycles with own oocytes where PGT was performed. This corresponds to 24.1% of aspirations with at least one mature oocyte. When stratified by age, the percentage of aspirations with PGT was 12.9% in women aged ≤ 34 years, 23.7% in women aged 35-39 years, and 33.4% in women aged ≥ 40 years.

The mean age of women who underwent PGT with their own oocytes was 38.3 (SD 3.97) and the age distribution included 17.6% in women aged ≤ 34 years, 20.2% in women aged 35-37 years, 19.7% in women 38-39 years and 42.5% in women ≥ 40 years.

The effect of PGT on the rate of delivery and miscarriage can be seen in Table 2. When stratified by age, PGT significantly decreased the miscarriage rate in all age categories, including women ≤ 34 years (p = 0.041) and women with oocyte donation (p = 0.002). Regarding the effect of PGT on the probability of achieving birth, the differences in births with and without PGT are again significantly greater with PGT in all age groups, including egg donation (p < 0.001).

Cumulative birth rates in REDLARA were calculated in a subgroup of 4,344 women who, in addition to their fresh transfers, had frozen super-numerary embryos for subsequent transfers, regardless of whether they were used during 2020. For calculating cumulative deliveries, this latter group best reflects cumulative chances,
because women without frozen embryos had their only chance after fresh transfer. The fresh transfer delivery rate is notably higher at all ages in women with frozen surplus embryos. Another interesting observation in this group of women who had surplus embryos was the less steep slope of the decline in deliveries with increasing age.

Fertility preservation

A total of 7,558 initiated cycles of fertility preservation egg vitrification were reported, of which 7,204 had at least one mature oocyte (95.3%). The age distribution of women has shown minimal changes in recent years and the proportion of women attempting fertility preservation at ≥38 remains very high (44.8%) (Figure 7). The mean (SD) number of vitrified oocytes in metaphase II was 7.04 (± 5.83), with wide variations according to the age of the woman. In women ≥ 34 years old the mean was 9.02 (± 7.05), in women 35-38 years it was 7.32 (± 5.73), in those 39-40 it was 5.77 (± 4.52) and in women ≥ 40 it was 4.54 (± 3.76) oocytes. In 95.1% of cases, the reason for oocyte vitrification was fertility postponement for reasons other than cancer, which represented the main reason for fertility preservation in 4.9% of cases.

Frozen embryo transfer

The proportion of TED cycles continues to increase, accounting for 66.6% of all transfers with own oocytes. This has been associated with a continued fall in the average number of fresh cycles initiated.
embryos transferred to 1.6. As reported in the past, pregnancy and delivery rates after TED were higher than after fresh transfers, regardless of the number of embryos transferred. This may seem surprising, considering that a large proportion of TED cycles are the result of failed fresh transfers. The main reason is the proportion of blastocyst-stage transfers, which is much higher in TED (86.3%) compared to only 53.6% after fresh transfers (splitting embryo). Again, this shows that it is the selection of the best blastocyst for transfer that produces the best results, either through morphology evaluation or after the addition of PGT.

The number of centers and cycles reporting PGT is increasing year after year. In 2020, 76.6% of centers reported PG from 24.1% of aspirations with at least one mature oocyte. PGT was used in 27,287 blastocysts, most of which were examined by next-generation sequencing (NGS). The proportion of aneuploidies was 49.8% of embryos in women ≤ 34 years of age, 59.9% of embryos in women between 35-39 years, and 77.1% of embryos in women ≥ 40 years. In addition, the proportion of aneuploidies in 3,166 embryos generated from oocyte donors (mean age 25.5 years) was 36.1%. As seen in Table 2, the use of PGT reduced miscarriage rates and increased delivery rates in all ages, including oocyte recipients.

Indeed, there is a benefit in using PGT to achieve greater reproductive efficiency at all ages. However, the question is whether it is cost-effective at all ages, which will depend largely on reproductive health financing policies. Regardless of a country’s wealth, when most treatments are funded out-of-pocket, most consumers belong to a subgroup of middle- or high-income individuals. In this subgroup there is a triad of families with fewer children, delayed childbearing and a progressive search for certainty. The question of the absolute benefit of the PGT prevails over the trade-off between costs for the benefit sought. This partly explains the increasing use of PGT technology to ensure, as far as possible, the birth of healthy children.

Unlike previous years, the REDLARA report calculates the cumulative delivery rate for aspirations that took place only during 2020. In this cohort of 11,101 aspirations, only 4,344 (39%) had surplus embryos available for future transfer. Therefore, if cumulative births are calculated from the entire cohort, the majority of women (61%) will not have a second chance of birth from the initial aspiration cycle. This is most likely due to the high proportion (34%) of women aged 40 or older. When the cumulative delivery rate was calculated only among women who had surplus frozen embryos available for future transfers, the chance of a birth after a new transfer was already higher at all ages.

### Table 2. Effect of PGT on delivery and miscarriage rate depending on the woman’s age in thawed egg transfer (TED) with own oocytes and TED with donated oocytes (2020)\(^{50}\)

<table>
<thead>
<tr>
<th>Age of women</th>
<th>FET with PGT</th>
<th>FET without PGT</th>
<th>PR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscarriage(^a)</td>
<td>Oocyte donors</td>
<td>11.1% (54/452)</td>
<td>18.2% (435/2391)</td>
</tr>
<tr>
<td>Autologous ≤ 34</td>
<td>11.1% (47/424)</td>
<td>14.9% (394/2640)</td>
<td>1.35 (1.01 a 1.79); &lt;0.001(^b)</td>
</tr>
<tr>
<td>Autologous 35 - 39</td>
<td>11.1% (98/879)</td>
<td>16.6% (516/3112)</td>
<td>1.49 (1.21 a 1.82); &lt;0.001(^b)</td>
</tr>
<tr>
<td>Autologous ≥ 40</td>
<td>13.9% (94/675)</td>
<td>21.9% (317/1449)</td>
<td>1.57 (1.27 a 1.94); &lt;0.001(^b)</td>
</tr>
<tr>
<td>Delivery(^a)</td>
<td>Oocyte donors</td>
<td>39.6% (352/890)</td>
<td>29.3% (1642/5600)</td>
</tr>
<tr>
<td>Autologous ≤ 34</td>
<td>40.9% (329/805)</td>
<td>32.7% (1866/5707)</td>
<td>0.80 (0.74 a 0.87); &lt;0.001(^b)</td>
</tr>
<tr>
<td>Autologous 35 - 39</td>
<td>36.7% (679/1866)</td>
<td>27.6% (2132/7724)</td>
<td>0.76 (0.71 a 0.81); &lt;0.001(^b)</td>
</tr>
<tr>
<td>Autologous ≥ 40</td>
<td>35.5% (513/1440)</td>
<td>19.5% (904/4636)</td>
<td>0.55 (0.50 a 0.60); &lt;0.001(^b)</td>
</tr>
</tbody>
</table>

\(^{50}\) FET = frozen embryo transfer; OD FET = Oocyte donation frozen embryo transfer; PGT = preimplantation genetic testing; PR = prevalence ratio.

\(^{a}\) For miscarriage the denominator is clinical pregnancies; for deliveries, the denominator is embryo transfers.

\(^{b}\) Likelihood of having a miscarriage. The reference group is ‘with PGT’.

\(^{c}\) Likelihood of delivery. The reference group is ‘with PGT’.
The delta generated by subsequent (cumulative) TED was also higher. Another interesting finding is the better outcome after sequential transfer of two blastocysts (1+1) compared to simultaneous transfer of two blastocysts and is best seen in women ≥ 34 years. Although the differences in delivery rates are not very large, the rate of multiple births is almost 20 times higher after simultaneous transfer of two blastocysts (1.6% vs. 30.5%, respectively) than after 1+1. The impact of multiple births in terms of perinatal mortality and preterm and extreme preterm births is multiplied by 4-9 times. In 2020, 65% of all multiple births were in women ≤ 34 years old and oocyte recipients. Therefore, a 1+1 blastocyst strategy in these two groups should significantly reduce multiple births while maintaining acceptable delivery rates.

**Conclusions**

Thirty-four percent of IVF-ICSI procedures were in women aged ≥ 40 years (patients with fewer oocytes and higher percentage of aneuploid embryos, higher rate of miscarriages) as opposed to the SART report (USA) 26%. Therefore, this chapter is very important to focus more on the context of our reality. The trend observed over
time, and due to the results, the ideal is to trans-
fer blastocysts not developing embryos; to per-
form PGT in order to select the euploid embryo
and decrease the percentage of miscarriages.

Success rates in women ≥ 40 years old are low: the LBR per transfer is 18.2% without PGT and
42.7% with PGT; the rates improve if they have
more oocytes and more blastocysts. For this
reason, we recommend banking oocytes or em-
byros through multiple procedures.

The ideal objective is to transfer a single embryo
to avoid a multiple pregnancies which often lead
to obstetric complications, especially in patients
≥ 40 years of age, who simply because of their
age present a high-risk pregnancy.

It is important to transmit the results for the
counseling of our population, to disseminate
and encourage oocyte freezing before the age of
36, in order to have a greater number of eggs
and better results.

**REFERENCES**


4. Hassold T, Chiu D. Maternal age-specific rates of numerical chromosome abnormalities with special reference to triso-
my. Hum Genet. 1985;70:11. DOI: 10.1007/BF00389450

5. Warburton D, Kline J, Stein-Z, Strobino B. Cytogenetic abnor-
malities in spontaneous abortions of recognized concep-
tions. In: Porter IH, ed. Perinatal Genetics: Diagnosis and

and mice: lessons from statistical model comparison. Hum

7. Wilcox AJ, Weiberg CR, O'Connor JF, Baird DD, Schlatterer JP,
Canfield RE, Armstrong EG, Nisula BC. Incidence of early loss
NEJM198807283190401

hormone on the ovarian transcriptome to inhibit primordial
DOI: 10.1530/REP-07-0719

9. Adhikari D, Liu K. Molecular mechanisms underlying the
activation of mammalian primordial follicles. Endocr Rev.

10. te Velde ER, Pearson PL. The variability of female reproduc-
org/10.1093/humupd/8.2.141

11. van Noord PA, Dubas JS, Dorland M, Boersma H, E te Vel-
de E. Age at natural menopause in a population-based
screening cohort: the role of menarche, fertility, and life-
style factors. Fertil Steril. 1997;68:95. DOI: 10.1016/s0015-
0282(97)81482-3
Assisted fertilization with own oocytes in women over 40 years of age: indications and results


15. Treloar SA, Do KA, Martin NG. Genetic influence on the age at menopause. Lancet. 1998;352:1084. DOI: 10.1016/S0140-6736(05)79753-1


29. Klein NA, Battaglia DE, Miller PB, Branigan EF, Giudice LC, Soules MR. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. J Clin Endocrinol Metab. 1996;81:1946. DOI: 10.1210/jcem.81.5.8626662


Rev Peru Ginecol Obstet. 2023;69(3) 11
42. DeWaay DJ, Syrop CH, Nygaard IE, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol. 2002;100:3. DOI: 10.1016/s0029-7844(02)02007-0


